FDA Grants Accelerated Approval to First Drug to Decrease Urine Protein Caused by Rare Kidney Disease

Calliditas Therapeutics’ Tarpeyo (budesonide) has won FDA accelerated approval for reducing a harmful urine protein in adults with a rare kidney disease, primary immunoglobulin A (IgA) nephropathy.
Source: Drug Industry Daily